AI-168
Cardiovascular
Program
Program snapshot
Indication: Cardiovascular disease (including hypertension)
Stage: Preclinical
IP: PCT filed (PCT/AU2024/051253)
Program Partner: Monash Biomedicine Discovery Institute / Victorian Heart Institute
About AI-168
AI-168 is a novel fixed-dose combination drug candidate comprising a cannabinoid and an off-patent pharmaceutical ingredient, for cardiovascular disease including hypertension. It was identified by AlgoraeOS as a high-confidence drug-combination candidate.
Preclinical studies conducted in partnership with Dr Kristen Bubb at the Monash Biomedicine Discovery Institute and Victorian Heart Institute have demonstrated compelling early efficacy: 94% endothelial restoration, 80% smooth muscle normalisation, and a 68% reduction in cardiomyocyte damage.
The current focus is completing pre-clinical work to assess AI-168’s performance across established cardiovascular disease models. Next steps are clinical trials, subject to pre-clinical success and regulatory approvals.
The Cardiovascular Opportunity
Cardiovascular disease refers to a class of diseases involving the heart or blood vessels, including hypertension, coronary artery disease, heart failure, stroke, and arrhythmias. It represents one of the largest areas of global pharmaceutical spending.
Current treatments manage symptoms but do not address underlying mechanisms across all patient cohorts. Demand for effective, novel therapeutics remains substantial and growing.
Key Data
Fixed-dose combination: cannabinoid + off-patent pharmaceutical ingredient
Preclinical efficacy: 94% endothelial restoration
Preclinical efficacy: 80% smooth muscle normalisation
Preclinical efficacy: 68% reduction in cardiomyocyte damage
Research partner: Dr Kristen Bubb, Translational Vascular Therapeutics Group, Monash / Victorian Heart Institute
Identified by AlgoraeOS from 500,000+ CBD-drug-cell line predictions
Program Lead
Dr Kristen Bubb
Cardiovascular Program Lead — Monash / Victorian Heart Institute
Dr Kristen Bubb holds a PhD in Physiology and leads the Translational Vascular Therapeutics Group, co-located at the Monash Biomedicine Discovery Institute and the Victorian Heart Institute. She completed training at Monash University and the William Harvey Research Institute in London, supported by a British Pharmacological Society International Fellowship in Clinical Pharmacology. Her research focuses on identifying novel therapeutic targets for cardiovascular diseases, with a particular focus on signalling molecules that interact with the vascular endothelium.
Other Programs
AI-116
Dementia
Stage: Preclinical | PCT Filed
Fixed-dose combination of CBD and donepezil. 53% cell viability vs 17% with donepezil alone in preclinical validation. PCT patent filed (PCT/AU2024/050791).
NTCELL
Parkinson’s
Stage: Phase 2 data under review
Alginate-coated capsule containing neonatal porcine choroid plexus cells. Phase 2 clinical trial data under scientific review. Predates the current dual-track strategy.
Sign Up for Email Updates
"*" indicates required fields